KDM1A and cancer: In conclusion, LSD1 inhibition could be instrumental to convert “cold” tumors (resistant to PD-1 blockade) in “hot” tumors (responsive to PD-1 therapy) and provides a means to target LSD1 to increase the efficacy of immunotherapy of poor immunogenic cancers.